Valeric Acid Composition for Gut-Brain Modulation in AUD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective intervention strategies for habitual alcohol binge drinking, and existing treatments for alcohol use disorder (AUD) have limited success, with no new drugs approved by the FDA in two decades, despite the association between the gut microbiome and microbial metabolites with drinking behavior being understudied.
Innovation Solution
Administering valeric acid or its pharmaceutically acceptable salt, such as sodium valerate, to modulate the gut microbiome and brain chemistry, increasing beneficial bacteria like Ileibacterium and Dubosiella, enhancing GABA levels, and altering gene expression in the amygdala to reduce alcohol consumption and anxiety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for alcohol use disorder are used, then current standard of care is maintained, but treatment effectiveness is limited with no new drugs approved in two decades
Solution Approach 1:
The patent changes the therapeutic parameter from conventional pharmacological targets to gut microbiome metabolites, specifically using valeric acid and its derivatives. This parameter shift in the treatment approach enables the discovery of new effective compounds (sodium valerate) that can reduce alcohol consumption, thereby improving treatment effectiveness while bypassing the stagnation in traditional drug development
Solution Approach 2:
The patent introduces gut microbiome metabolites, particularly valeric acid and sodium valerate, as intermediary substances that mediate between the gut microbiome and brain chemistry. These intermediaries modulate GABA levels and gene expression in the amygdala, providing a novel mechanism for reducing alcohol consumption that differs from existing direct-acting pharmaceuticals
2Quantity of substance
If valeric acid or sodium valerate is administered to reduce alcohol consumption, then alcohol consumption and blood ethanol concentration are reduced, but the mechanism involves complex modulation of gut microbiome, GABA levels, and gene expression
Solution Approach 1:
Sodium valerate serves as a key intermediary that connects gut microbiome modulation to central nervous system effects. It is converted to valeric acid in the body, which then influences GABA synthesis and gene expression, providing a multi-level mediation mechanism that achieves alcohol reduction through coordinated biological pathways
Solution Approach 2:
The therapeutic mechanism is segmented into distinct actionable components: (1) administration of sodium valerate, (2) conversion to valeric acid, (3) modulation of gut microbiome composition, (4) enhancement of GABA levels, and (5) alteration of gene expression in the amygdala. This segmentation allows for targeted intervention at multiple points in the causal chain
3Reliability
If sodium valerate is used to treat alcohol use disorder, then anxiety-like behavior is improved and gut microbiome composition is shifted, but requires sustained supplementation regimen
Solution Approach 1:
The patent employs continuous supplementation with sodium valerate to maintain therapeutic effects on alcohol consumption and anxiety. The sustained administration ensures continuous modulation of gut microbiome and GABA levels, preventing relapse and maintaining long-term behavioral changes necessary for treating alcohol use disorder
Solution Approach 2:
Sodium valerate supplementation leverages the body's existing metabolic pathways, being converted endogenously to valeric acid which then acts on GABAergic systems. The body's own conversion mechanisms and existing neurochemical pathways are harnessed to produce the therapeutic effect, reducing the need for complex external delivery systems
Data Source
AI summary
Disclosed are agents, compositions, and methods including valeric acid, or a pharmaceutically acceptable salt thereof or a derivative thereof, for treating or preventing alcohol use disorder or alcohol risk consumption.